Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vessilen Kit is a sterile medical device developed by Epitech Group SpA for endovesical (intravesical) instillation. It is designed to treat inflammatory and dysmetabolic conditions of the bladder, such as interstitial cystitis and chronic cystitis, by promoting the restoration of urothelial surface integrity. The kit contains a combination of adelmidrol and sodium hyaluronate. Adelmidrol is a synthetic ALIAmide (Autacoid Local Injury Antagonism amide) derivative of azelaic acid that acts as a mast cell modulator by restoring physiological levels of palmitoylethanolamide (PEA), thereby controlling neuroinflammation and mast cell degranulation in the bladder wall. Sodium hyaluronate, a glycosaminoglycan, works synergistically to re-establish the protective glycosaminoglycan (GAG) layer of the urothelium, providing a physical barrier against irritants in the urine. The product is classified as a Class III medical device and is commercially available in Italy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Vessilen Kit.